We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 39

Australian Federal Court decides protecting your brand against generic pharmaceuticals is not a misuse of market power

  • Bird & Bird
  • -
  • Australia
  • -
  • March 18 2015

In a decision which will be welcomed by many pharmaceutical companies the Federal Court of Australia recently dismissed proceedings instituted by the

Substantial market power now you have it, now you don’t. The decision in ACCC v Pfizer

  • Johnson Winter & Slattery
  • -
  • Australia
  • -
  • March 17 2015

The recent Federal Court decision in ACCC v Pfizer serves as strong reminder that market power is not static but must be assessed in the context of a

ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk

  • Herbert Smith Freehills LLP
  • -
  • Australia
  • -
  • March 3 2015

The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had misused

ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk

  • Herbert Smith Freehills LLP
  • -
  • Australia
  • -
  • March 3 2015

In brief The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had

Pfizer case shows protecting your own position isn't anti-competitive

  • Clayton Utz
  • -
  • Australia
  • -
  • March 2 2015

Commercial strategies and practices used by Pfizer to counter the expected loss of revenue caused by the expiry of its patent over Lipitor, its

ACCC v Pfizer judgment summary and ramifications

  • Piper Alderman
  • -
  • Australia
  • -
  • February 27 2015

On 25 February 2015, Justice Flick of the Federal Court of Australia ruled in favour of Pfizer Australia Pty Ltd (Pfizer), dismissing the Australian

Australian antitrust enforcement focuses on healthcare & life sciences

  • Jones Day
  • -
  • Australia
  • -
  • December 22 2014

The Australian Competition and Consumer Commission (ACCC) has continued its focus on the healthcare and life sciences sectors this year, most

Hospital’s by-laws flatline on the competition table

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • December 22 2014

The ACCC has launched proceedings in the Federal Court against Little Company of Mary Health Ltd and its subsidiary Calvary Health Care Riverina Ltd

Federal government’s “action plan” for Australia will the direct selling sector be affected?

  • Addisons
  • -
  • Australia
  • -
  • December 2 2014

In November 2014 the Australia federal government released its Industry Innovation and Competitiveness Agenda (the Agenda), a report1 outlining the

ACCC imposes strict transparency provisions on updated Medicines Australia Code of Conduct

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • October 28 2014

Roll-out of a new edition of Medicines Australia’s Code of Conduct has struck a roadblock, with the ACCC requesting that Medicines Australia amend